Lv6
1820 积分 2023-09-20 加入
NK2R control of energy expenditure and feeding to treat metabolic diseases
5天前
已完结
Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers
27天前
已完结
Abstract B168: Identification of STX-241, a CNS-penetrant and mutant-selective EGFR inhibitor with activity on osimertinib-resistant C797x mutations
1个月前
已关闭
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
2个月前
已完结
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models
3个月前
已完结
Understanding the complexity of p53 in a new era of tumor suppression
5个月前
已完结
Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery
8个月前
已完结
Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers
8个月前
已完结
SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status
8个月前
已完结
Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer
10个月前
已完结
皖公网安备34019202002308
